Section/item	Item No	Recommendation	Reported on page No(p)/ line No(l)
Title and abstract			
Title	1	Identify the study as an economic valuation or use more specific terms such as "cost- effectiveness analysis", and describe the interventions compared.	P1 3
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	P1I30 – p2 I11
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions.	P2 30 – p3 27
Methods			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	P3 I34-44
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	P3 13–24, p1 1, p4 12-35
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	P5 53 – p6 17
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	P5 I5-8
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	P4 12-21
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	P4 I24-30
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	p7 l21-53
Measurement of effectiveness	11a	<i>Single study-based estimates:</i> Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	Not applicable
	11b	<i>Synthesis-based estimates:</i> Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	P4 39-52
Measurement and valuation of preference based outcomes	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	Not applicable

Estimating	13a	Single study-based economic evaluation:	Not applicable
resources and	15a	Describe approaches used to estimate resource	Not applicable
costs		use associated with the alternative	
00000		interventions. Describe primary or secondary	
		research methods for valuing each resource item	
		in terms of its unit cost. Describe any	
		adjustments made to approximate to opportunity	
		costs.	
	13b	Model-based economic evaluation: Describe	P4 I40-55, p5 I6 –
	150	approaches and data sources used to estimate	p6 l24, online
		resource use associated with model health states.	supplement
		Describe primary or secondary research methods	supplement
		for valuing each resource item in terms of its	
		unit cost. Describe any adjustments made to	
		approximate to opportunity costs.	
Currency, price	14	Report the dates of the estimated resource	P6 17-23
date, and	14	quantities and unit costs. Describe methods for	1011/-23
conversion		adjusting estimated unit costs to the year of	
conversion		reported costs if necessary. Describe methods for	
		converting costs into a common currency base	
		and the exchange rate.	
Choice of model	15		D2 47 m4 21
Choice of model	15	Describe and give reasons for the specific type	P3 47 – p4 21,
		of decision analytical model used. Providing a	figure 1
		figure to show model structure is strongly	
A	16	recommended.	
Assumptions	16	Describe all structural or other assumptions	P5 41-p6 23
A 1 (* 1	17	underpinning the decision-analytical model.	
Analytical	17	Describe all analytical methods supporting the	P6 26 – p7 17
methods		evaluation. This could include methods for	
		dealing with skewed, missing, or censored data;	
		extrapolation methods; methods for pooling	
		data; approaches to validate or make adjustments	
		(such as half cycle corrections) to a model; and	
		methods for handling population heterogeneity	
		and uncertainty.	
Results	10		T 11 64 62
Study parameters	18	Report the values, ranges, references, and, if	Tables S1, S2
		used, probability distributions for all parameters.	(supplement)
		Report reasons or sources for	
		distributions used to represent uncertainty where	
		appropriate. Providing a table to show the input	
	<u> </u>	values is strongly recommended.	
Incremental costs	19	Report the values, ranges, references, and, if	Table 1, figures S1,
and outcomes		used, probability distributions for all parameters.	S2 (supplement)
		Report reasons or sources for	
		distributions used to represent uncertainty where	
			1
		appropriate. Providing a table to show the input values is strongly recommended.	

Characterising uncertainty	20a	Single study-based economic evaluation: Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact of methodological assumptions (such as discount rate, study perspective). Model-based economic evaluation: Describe the	Not applicable P8 44 – p9 28,
	200	effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	figure 3, table 1
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or costeffectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	Not applicable
Discussion			
Study findings, limitations, generalisability, and current knowledge	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.	P10 6-20
Other			
Source of funding	23	Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	Acknowledgements and added disclosure
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	Acknowledgements and added disclosure